Skip to main content

Profiles

Roivant Sciences

Roivant Sciences is an American-Swiss pharmaceutical and biotechnology company based in New York City, with offices in Boston, Massachusetts and Basel, Switzerland. It was founded by Vivek Ramaswamy in 2014.[1]

History

Ramaswamy incorporated the company on April 7, 2014 in Bermuda.[2][3]

On September 20, 2017, Roivant announced the launch of Datavant, "a new company focused on employing artificial intelligence to improve the clinical trial process."[4] Travis May and Sam Roosz are credited as co-founders.[5]

In April 2018, Roivant announced that it was joining forces with Arbutus Biopharma to launch Genevant Sciences, a jointly-owned venture focused on “the discovery, development, and commercialization of a broad range of RNA-based therapeutics” aiming for “5-10 product candidates into the clinic by 2020.”[6]

COVID-19

On February 26, 2021, Roivant announced its acquisition of Silicon Therapeutics.[7]

Organization

Roivant is a member company of the Biotechnology Innovation Organization (BIO).[8]

Personnel

Name Position Notes
Vivek Ramaswamy Founder[2:1] Strive Asset Management, Campus Venture Network
Jo Chen General Counsel[9] JHL Capital Group, Bain Capital, D. E. Shaw & Co., Weil, Gotshal & Manges
Alex Gasner Executive Vice President Bee
Matt Gline Chief Executive Officer Goldman Sachs, Fourthree, Barclays
Kelly Graff Head of People Interferometrics, Delta Analysis Group, Entegra Systems, Stevenson Search Partners, Occam Global, American Cancer Society (ACS)
Drew Krames Chief Information Officer Pivotal, VMWare, OneCloud
Rakhi Kumar Chief Accounting Officer The Medicines Company, Ernst & Young, NeuroPace
Amy Mahery Chief Commercial Officer EMD Serono
Matt Maisak Chief Operating Officer Axovant Sciences, Covant Therapeutics, Roche, Projects Abroad
Richard Pulik Chief Financial Officer Novartis, Merrill Lynch, UBS Investment Bank, Monitor Group, William Alanson White Institute
Srini Ramanathan Chief Development Officer Horizon Therapeutics, AbbVie, Gilead Sciences, Asian University for Women (AUW)
Mayukh Sukhatme President and Chief Investment Officer Narragansett Asset Management, Apothecary Capital, Sigma Capital, Sio Capital Management, Hutchin Hill Capital, Apple Tree Partners (ATP)
Frank Torti Vant Chair Telavant, Immunovant, New Enterprise Associates (NEA)
Eric Venker President and Chief Operating Officer NewYork-Presbyterian Hospital, Yale New Haven Hospital

Investors

Investors in Roivant include:[10][11][12]

  • Dexcel Pharma
  • Eventide
  • Fidelity Investments
  • Founders Fund
  • NovaQuest Capital Management
  • Palantir Technologies
  • Patient Square Capital
  • QVT Financial
  • RTW Investments
  • SoftBank Vision Fund[13]
  • Sumitomo Pharma
  • Suvretta Capital Management
  • Viking Global Investors

Portfolio

Companies in Roivant's portfolio include:[10:1][14][15]

  • Affivant Sciences
  • Arbutus Biopharma[16]
  • Axovant Sciences
  • Covant Therapeutics
  • Datavant
  • Dermavant Sciences
  • Enzyvant[4:1]
  • Gen-t Science
  • Genevant Sciences
  • Hemavant Sciences
  • Immunovant
  • Kinevant
  • Lokavant
  • Medallion
  • Myovant Sciences[4:2]
  • Priovant Therapeutics
  • Proteovant Therapeutics
  • Psivant Therapeutics
  • Silicon Therapeutics[7:1]
  • Telavant
  • Urovant[4:3]
  • VantAI

Activities

Roivant has provided notable funding to:

  1. Company Overview. Roivant. Retrieved May 27, 2024, from https://web.archive.org/web/20240527231807/https://www.roivant.com/about/company ↩︎

  2. Lee, S. (2023, February 21). Roivant Sciences Announces Change to its Board of Directors. Roivant Sciences. https://web.archive.org/web/20230626001023/https://investor.roivant.com/news-releases/news-release-details/roivant-sciences-announces-change-its-board-directors ↩︎ ↩︎

  3. Bermuda Registrar of Companies. (2017, January 10). Roivant Sciences Ltd. OpenCorporates. http://archive.today/2023.06.26-015348/https://opencorporates.com/companies/bm/48931 ↩︎

  4. Davis, P., & Roosz, S. (2017, September 20). Roivant Sciences Launches Datavant to Improve Clinical Trials with Artificial Intelligence. Roivant Sciences. https://web.archive.org/web/20210805175607/https://roivant.com/roivant-sciences-launches-datavant-to-improve-clinical-trials-with-artificial-intelligence.html ↩︎ ↩︎ ↩︎ ↩︎

  5. Sam Roosz. Federation of American Scientists. Retrieved December 7, 2023, from https://web.archive.org/web/20231207011907/https://fas.org/expert/sam-roosz/ ↩︎

  6. Tolmie, T., & Schull, D. (2018, April 11). Arbutus and Roivant Launch Genevant Sciences with Industry-Leading Platform to Develop Broad Range of RNA Therapeutics for Genetic Diseases. Arbutus Biopharma. https://web.archive.org/web/20230207071630/https://investor.arbutusbio.com/news-releases/news-release-details/arbutus-and-roivant-launch-genevant-sciences-industry-leading ↩︎

  7. Landenberger, L. (2021, February 26). Roivant acquires Silicon Therapeutics for $450M in equity. BioWorld. https://web.archive.org/web/20240527233329/https://www.bioworld.com/articles/504117-roivant-acquires-silicon-therapeutics-for-450m-in-equity?v=preview ↩︎ ↩︎

  8. BIO Member Directory. Biotechnology Innovation Organization. Retrieved September 30, 2022, from https://web.archive.org/web/20220930103715/https://www.bio.org/bio-member-directory ↩︎

  9. Leadership. Roivant. Retrieved May 27, 2024, from https://web.archive.org/web/20240527231824/https://www.roivant.com/about/leadership ↩︎

  10. Roivant Sciences - Financials. Crunchbase. Retrieved May 27, 2024, from https://www.crunchbase.com/organization/roivant-sciences/company_financials ↩︎ ↩︎

  11. Private Equity Round - Roivant Sciences. Crunchbase. Retrieved May 27, 2024, from https://www.crunchbase.com/funding_round/roivant-sciences-private-equity--fb72be6a ↩︎

  12. Company Overview. Roivant. Retrieved May 27, 2024, from http://archive.today/2024.05.27-231807/https://www.roivant.com/about/company ↩︎

  13. Portfolio. SoftBank Vision Fund. Retrieved May 5, 2023, from https://web.archive.org/web/20230505171511/https://visionfund.com/portfolio ↩︎

  14. Our Companies. Roivant. Retrieved May 27, 2024, from https://web.archive.org/web/20240527231832/https://www.roivant.com/companies ↩︎

  15. Our Companies. Roivant. Retrieved August 15, 2022, from https://web.archive.org/web/20220815141030/https://www.roivant.com/companies ↩︎

  16. Arbutus Biopharma - Funding, Financials, Valuation & Investors. Crunchbase. Retrieved August 25, 2023, from https://www.crunchbase.com/organization/arbutus-biopharma/company_financials ↩︎

  17. How We’re Funded. Alliance for Aging Research. Retrieved August 6, 2020, from https://web.archive.org/web/20200806210808/https://www.agingresearch.org/about-us/how-were-funded/ ↩︎

  18. Annual Report 2018. (2018). Bipartisan Policy Center. https://web.archive.org/web/20220108073604/https://bipartisanpolicy.org/download/?file=/wp-content/uploads/2019/07/Annual-Report-2018.pdf ↩︎